drug · small molecule
nintedanib
Phase 3updated 3mo agoby Cloudbreak Therapeutics LLC🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 33 investigational indications.
indications
indications
Pulmonary Fibrosis
targets
Platelet-derived growth factor receptorVascular endothelial growth factor receptorFibroblast growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying nintedanib
- phase2Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
- —Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
- phase1A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
- —Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
- phase1A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
- phase1Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
- —Real-life-persistence to Antifibrotic Treatments
- phase2Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
News(2)
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.biopharma_dive · 1mo ago
- Avalyn, in pursuit of better lung drugs, banks $300M in an IPOThe biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.biopharma_dive · 3mo ago
Data sources
last refreshed 41m ago
Found something off?
comments(0)
5-min edit window · permanent after that